SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Vistagen Therapeutics, Inc. (NASDAQ: VTGN)

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Vistagen Therapeutics, Inc. on behalf of investors who purchased or acquired the company's common stock between April 1, 2024, and December 16, 2025, alleging misrepresentations related to the company's clinical trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is an investigational pherine candidate for the acute treatment of social anxiety disorder [4]. - Investors who wish to serve as lead plaintiff must file papers by March 16, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for its clients since 1993 and has a strong track record in class action litigation [5].